A Clinical Study of McGhan Corporation-Style 410 Silicone-Filled Breast Implants
[Protocol 06-024] |
Disa, Joseph, MD |
A Long-Term Study of Sexual and Reproductive Health in Women with Breast Cancer and Lymphoma
[Protocol 12-249] |
Goldfarb, Shari, MD |
A Phase I Study of BKM120 and Olaparib in Patients with High-Grade Serous Ovarian Cancer
[Protocol 12-233] |
Bell-McGuinn, Katherine, MD, PhD |
A Phase I Study of Enzalutamide (MDV3100) in Patients with Previously Treated Metastatic Breast Cancer
[Protocol 12-155] |
Traina, Tiffany, MD |
A Phase I Study of GL-ONC1 for Treating Malignant Pleural Effusion
[Protocol 12-169] |
Rusch, Valerie, MD |
A Phase I Study of HER2/neu DNA Immunization for Patients with Metastatic or High-Risk Breast Cancer
[Protocol 04-101] |
Gilewski, Teresa, MD |
A Phase I Study of Topical Calcitriol (Compound 31543) to Prevent Hair Loss in Women Receiving Paclitaxel for Advanced Breast Cancer
[Protocol 11-205] |
Lacouture, Mario, MD |
A Phase I Study of Whole Brain Radiation Therapy plus Sorafenib for Patients with Breast Cancer Brain Metastases
[Protocol 12-046] |
Seidman, Andrew, MD |
A Phase I-II Study of Dasatinib plus Paclitaxel in Patients with Metastatic Breast Cancer
[Protocol 08-122] |
Fornier, Monica, MD |
A Phase I/II Clinical Trial of Temsirolimus plus Neratinib for Patients with Metastatic HER2-Amplified or Triple-Negative Breast Cancer
[Protocol 10-005] |
Chandarlapaty, Sarat, MD, PhD |
A Phase I/II Study of Intrathecal Trastuzumab in Women with HER2-Positive Breast Cancer that Spread to the Spinal Fluid
[Protocol 12-123] |
Pentsova, Elena, MD |
A Phase IB Study of BKM120 plus MEK162 in Select Patients with Advanced Solid Tumors
[Protocol 11-117] |
Gounder, Mrinal, MD |
A Phase Ib Study of Trastuzumab-MCC-DM1, Paclitaxel, and Pertuzumab in Patients with HER2-Positive, Locally Advanced or Metastatic Breast Cancer Who Previously Received Trastuzumab
[Protocol 09-093] |
Modi, Shanu, MD |
A Phase II Study of Abiraterone, Exemestane, or Both in Postmenopausal Women with ER-Positive Metastatic Breast Cancer
[Protocol 12-140] |
Traina, Tiffany, MD |
A Phase II Study of Abraxane with or without Tigatuzumab in Patients with Metastatic Triple-Negative Breast Cancer
[Protocol 11-082] |
Traina, Tiffany, MD |
A Phase II Study of Adjuvant Bevacizumab, Metronomic Chemotherapy, Diet, and Exercise After Preoperative Chemotherapy for Breast Cancer
[Protocol 11-063] |
Dickler, Maura, MD |
A Phase II Study of Cabozantinib in Women with Hormone Receptor-Positive Breast Cancer that Spread to the Bone
[Protocol 12-091] |
Fornier, Monica, MD |
A Phase II Study of Dose-Dense Doxorubicin and Cyclophosphamide followed by Eribulin Mesylate for the Adjuvant Treatment of Early-Stage Breast Cancer
[Protocol 10-190] |
Traina, Tiffany, MD |
A Phase II Study of Fulvestrant Alone or with GDC-0941 or GDC-0980 in Women with Advanced Breast Cancer Resistant to Aromatase Inhibitor Therapy
[Protocol 12-029] |
Dickler, Maura, MD |
A Phase II Study of Paclitaxel, Trastuzumab, and Pertuzumab for the Treatment of Metastatic HER2-Positive Breast Cancer
[Protocol 10-142] |
Dang, Chau, MD |
A Phase II Study of Partial Breast Irradiation for Select Patients with Early Invasive or Noninvasive Breast Cancer
[Protocol 10-114] |
Powell, Simon, MD |
A Phase II Study of Repeat Breast-Preserving Surgery and 3D-Conformal Partial Breast Re-Irradiation for Local Recurrence of Breast Cancer
[Protocol 10-152] |
McCormick, Beryl, MD |
A Phase II Study of Veliparib plus Temozolomide, Veliparib plus Carboplatin and Paclitaxel, or Carboplatin and Paclitaxel with Placebo in Patients with BRCA Mutations and Metastatic Breast Cancer
[Protocol 12-122] |
Robson, Mark, MD |
A Phase III Study of Accelerated Whole Breast Radiation Therapy with a Boost versus Standard Whole Breast Radiation with a Boost in Women with Early-Stage Breast Cancer (RTOG 1005)
[Protocol 12-158] |
Parhar, Preeti, MD |
A Phase III Study of BKM120 with Fulvestrant in Postmenopausal Women with Locally Advanced or Metastatic Hormone Receptor-Positive HER2-Negative Breast Cancer
[Protocol 12-290] |
Dickler, Maura, MD |
A Phase III Study of Chemotherapy and Trastuzumab with or without Pertuzumab in Patients with Operable HER2-Positive Breast Cancer
[Protocol 12-115] |
Dang, Chau, MD |
A Phase III Study of Hormone Therapy with and without Chemotherapy in Patients with HER2-Negative Breast Cancer and 1-3 Positive Lymph Nodes and a Recurrence Score of 25 or Less
[Protocol 12-118] |
Lake, Diana, MD |
A Phase III Study of the Value of Early Local Therapy for the Intact Primary Tumor in Patients with Metastatic Breast Cancer
[Protocol 11-190] |
King, Tari, MD |
A Pilot Study of a Geriatric-Specific Psychoeducational Intervention for Elderly Cancer Patients
[Protocol 09-116] |
Roth, Andrew, MD |
A Pilot Study of Multi-Beam Intensity-Modulated Radiation Therapy for Node-Positive Breast Cancer Requiring Treatment of the Internal Mammary Lymph Nodes
[Protocol 10-025] |
Ho, Alice, MD |
A Pilot Study of Single-Dose Ipilimumab and/or Cryoablation in Women with Early-Stage Breast Cancer Scheduled for Mastectomy
[Protocol 11-202] |
McArthur, Heather, MD |
A Pilot Study Surveying Female Cancer Patients' Preference for Sexual Health Interventions
[Protocol 10-034] |
Carter, Jeanne, PhD |
A Pilot Study to Identify Patient Factors Impacting Adherence to Oral Chemotherapy
[Protocol 11-194] |
Ginex, Pamela, RN, EDD |
A Prospective, Longitudinal Study to Examine Time-Dependent Neurocognitive Changes in Patients with Breast Cancer Receiving Adjuvant Chemotherapy
[Protocol 07-130] |
Ahles, Tim, PhD |
A Study Assessing the Feasibility of Treatment with Paclitaxel, Trastuzumab, and Lapatinib in Women with HER2-Positive Early-Stage Breast Cancer
[Protocol 13-002] |
Dang, Chau, MD |
A Study of Non-Hormonal Vaginal Moisturizer in Hormone Receptor-Positive Postmenopausal Cancer Survivors
[Protocol 12-232] |
Carter, Jeanne, PhD |
Acupuncture for Chronic Lymphedema After Breast Cancer Treatment
[Protocol 12-210] |
Cassileth, Barrie, PhD |
An Interactive e-Health Program to Promote Health Behaviors Among Cancer Survivors
[Protocol 12-090] |
Ostroff, Jamie, PhD |
Assessment of a Customized Computer Program for Reducing Fears of Breast Cancer Recurrence
[Protocol 11-204] |
Lichtenthal, Wendy, PhD |
Clinical and Biological Predictors of Chemotherapy Toxicity in Older Adults
[Protocol 12-089] |
Tew, William, MD |
Clinical Significance of Germline BRCA Mutations
[Protocol 96-051] |
Offit, Kenneth, MD |
Developing Culturally Tailored Support Groups for Chinese Immigrants with Breast Cancer: A Pilot Study
[Protocol 12-105] |
Leng, Jennifer, MD, MPH |
Development of Group Interventions for Breast Cancer Survivors
[Protocol 12-291] |
Lichtenthal, Wendy, PhD |
EMPOWER Study: Promoting Breast Cancer Screening in Women Who Survived Childhood Cancer
[Protocol 10-104] |
Oeffinger, Kevin, MD |
Ethnic Differences in the Impact of Breast Cancer on Employment Status, Financial Situation, and Quality of Life
[Protocol 10-071] |
Blinder, Victoria, MD |
Evaluating the Causes of Cancer in Young Patients
[Protocol 09-068] |
Stadler, Zsofia, MD |
Impact of Breast Conservation Surgery on Surgical Outcomes and Cosmetic Appearance in Patients with Multiple Tumors in One Breast
[Protocol 13-023] |
Van Zee, Kimberly, MD |
Inamed Corporation-Style 410 Silicone-Filled Breast Implant Continued Assess Reconstruction/Revision Expansion (CARE) Clinical Study
[Protocol 06-076] |
Cordeiro, Peter, MD |
Measuring Patient Satisfaction in Breast Surgery: Development and Validation of a Patient-Reported Outcomes Instrument
[Protocol 05-058] |
Pusic, Andrea, MD, MHS |
Molecular Mechanisms of Clinical Resistance to Anti-HER2 Therapy Among Patients with HER2-Amplified Breast Cancer
[Protocol 06-163] |
Chandarlapaty, Sarat, MD, PhD |
